RedHill Biopharma Debt-to-Equity Ratio Growth & History (RDHL)
RedHill Biopharma's debt-to-equity ratio was 0.25 for fiscal 2025.
View full RedHill Biopharma company overviewRedHill Biopharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.25 | — | — |
| 2023 | 2023-12-31 | 0.57 | — | — |
| 2021 | 2021-12-31 | 9.89 | 3.63 | +57.85% |
| 2020 | 2020-12-31 | 6.27 | 6.20 | +9758.65% |
| 2019 | 2019-12-31 | 0.06 | — | — |
RedHill Biopharma quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.25 | — | — |
| Q2 2024 | 2024-06-30 | 9.15 | 8.49 | +1290.15% |
| Q4 2023 | 2023-12-31 | 0.57 | — | — |
| Q2 2023 | 2023-06-30 | 0.66 | — | — |
| Q4 2021 | 2021-12-31 | 9.89 | 3.63 | +57.85% |
| Q2 2021 | 2021-06-30 | 2.97 | 0.52 | +21.38% |
| Q4 2020 | 2020-12-31 | 6.27 | 6.20 | +9758.65% |
| Q2 2020 | 2020-06-30 | 2.45 | 2.32 | +1817.48% |
| Q4 2019 | 2019-12-31 | 0.06 | — | — |
| Q2 2019 | 2019-06-30 | 0.13 | — | — |
RedHill Biopharma debt-to-equity ratio trends
Over the last five fiscal years, RedHill Biopharma's debt-to-equity ratio decreased from 6.27 to 0.25, a change of −6.02. The latest reported quarter, Q4 2025, shows 0.25.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗